8:54 AM ET
8-K
Clinical Trial Data
Kodiak Sciences Clinical Trial Data
Kodiak Sciences announced that its Phase 3 DAYBREAK study in wet age-related macular degeneration (wAMD) met its primary endpoints for both Zenkuda and tabirafusp-ted. Both drugs demonstrated non-inferiority in vision gains compared to aflibercept, with Zenkuda showing 6-month durability in 54% of patients. The company plans to submit a multi-indication Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026.